The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2022 | Pooled analysis from the CRICKET and CAVE trials for the treatment of mCRC
Erika Martinelli, MD, PhD, University of Campania Luigi Vanvitelli, Caserta, Italy, discusses the findings from an analysis of data pooled from the CRICKET (NCT02296203) and CAVE (NCT04561336) trials. The positive results of the rechallenge third-line treatment with cetuximab, such as the resulting median progression-free survival (PFS) of 3.9 months and median overall survival (OS) of 16.9 months, are discussed. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.
